Two-and-a-half-years into Diverge, and what a journey it has been.
2019 was all about the digital strategies of big pharma towards digital biomarkers, patient companions, platform and ecosystem thinking.
2020 was all about … COVID-19 obviously, but it also brought 2 most inspiring projects, enabling me to combine a historical passion for life sciences and medical biotech with a more recent interest in digital health.
Well into 2021, both projects have been extended:
- into a structural lead in Strategy, Business and Client development for my favourite preclinical CRO focused on in vivo pharmacology of novel Alzheimer, Parkinson and Huntington therapies, and
- into a Project and Partnership management role for the design-and-build of a data-platform enabled experimental hub that lowers the threshold to validate innovation ideas build on the better unlocking, exchange & sharing of health data.
Two worlds of real opportunity for multi-stakeholder value creation in healthcare, my number one ambition. Truly humbled and thankful for that.